Deep-Dive Due Diligence AI Generated Report on Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.

Market Score
  65
Price Target
  $7.71
Squeeze Score
  30
Stock Type
  Speculative
Sentiment
  Mixed
Primary Catalyst
  Earnings report
Ethical Rating
  C
Tags
  biotech, high volatility, insider ownership, overvalued

Zhengye Biotechnology Soars Amid Sales Decline, High Valuation

Summary: Zhengye Biotechnology has experienced significant stock price and volume increases recently, with a remarkable performance over the last month and quarter. Despite these gains, the company has been struggling with declining sales year-over-year and quarter-over-quarter, which raises concerns about its fundamental health. High insider ownership and a low debt-to-equity ratio provide some stability, but the high P/E ratio suggests the stock might be overvalued given its current earnings.

ZYBT_OUT_1 [2025-04-16 12:38:45 -0400] 3400 Bytes | 914 tokens | Cum: 914 tkns (11.43% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Zhengye Biotechnology (ZYBT) which is at 7.1400 up from 5.7700. So, I pulled together a bunch of data for you to look over real fast. It's still early, 12:38:44 PM on Wed Apr 16, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Zhengye Biotechnology (ZYBT)
IPO: 2025-01-07 (3 Months Ago)
Market Cap: $252,122,120
Shares Outstanding: 47,390,000
Exchange: XNAS
Description: Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.

Here’s a list of headlines for Zhengye Biotechnology:

Jan-14-25 12:00PM - Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option
Jan-08-25 12:00PM - Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering
Jan-06-25 05:50PM - Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering

Prior AI Reports for ZYBT:
1. 2025-04-02 – Score: 1 – Target: 7.6800 – Highs: 7.3500 / 5.4600 / 4.83
high-volume-and-moderate-returns-fuel-optimistic-market-outlook
2. 2025-03-26 – Score: 1 – Target: 9.7000 – Highs: 10.0000 / 7.9894 / 5.67
investor-interest-surges-as-company-shows-remarkable-improvement
3. 2025-03-25 – Score: 1 – Target: 8.6700 – Highs: 9.2793 / 10.0000 / 7.99
zhengye-biotech-soars-amid-strong-momentum-despite-sales-decline
4. 2025-03-21 – Score: 40 – Target: 5.2800 – Highs: 4.9000 / 5.8500 / 9.28
zhengye-biotech-faces-volatility-amidst-dwindling-sales

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Zhengye Biotechnology (ZYBT).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ZYBT_IN_2 [2025-04-16 12:38:46 -0400] 3 Bytes | 2 tokens | Cum: 916 tkns (11.45% of 8k)
==========================================================================

NEX

ZYBT_OUT_3 [2025-04-16 12:38:46 -0400] 987 Bytes | 295 tokens | Cum: 1211 tkns (15.14% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-26T13:18:00Z - Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON....
A2 - 2025-03-26T12:11:54Z - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - AquaBounty Techs (NASDAQ:AQB), Acla...
A3 - 2025-03-26T11:07:32Z - Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session -...
A4 - 2025-03-26T11:07:40Z - Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session -...
A5 - 2025-03-26T09:00:09Z - Why GameStop Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - AquaBoun...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ZYBT_IN_4 [2025-04-16 12:38:46 -0400] 2 Bytes | 2 tokens | Cum: 1213 tkns (15.16% of 8k)
==========================================================================

A1

ZYBT_OUT_5 [2025-04-16 12:38:47 -0400] 1181 Bytes | 429 tokens | Cum: 1642 tkns (20.52% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Pre-market Movers: OSRH, SURG, BLNE, HUMA, TNON.**Date: 2025-03-26Source: {'uri': 'finanznachrichten.de', 'dataType': 'news', 'title': 'FinanzNachrichten.de'}URL: https://www.finanznachrichten.de/nachrichten-2025-03/64934114-pre-market-movers-osrh-surg-blne-huma-tnon-020.htmOTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).

In the Green

OSR Holdings, Inc. (OSRH) is up over 173% at $4.37. SurgePays, Inc. (SURG) is up over 74% at $2.41. Beeline Holdings, Inc. (BLNE) is up over 52% at $2.86. GameStop Corp. (GME) is up over 15% at $29.38. Visionary Holdings Inc. (GV) is up over 11% at $3.56. Perimeter Solutions, Inc. (PRM) is up over 9% at $9.94. TherapeuticsMD, Inc. (TXMD) is up over 9% at $1.00. Titan America SA (TTAM) is up over 8% at $14.84. AleAnna, Inc. (ANNA) is up over 7% at $8.30. Global Interacti

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ZYBT_IN_6 [2025-04-16 12:38:47 -0400] 3 Bytes | 2 tokens | Cum: 1644 tkns (20.55% of 8k)
==========================================================================

MOR

ZYBT_OUT_7 [2025-04-16 12:38:48 -0400] 1028 Bytes | 355 tokens | Cum: 1999 tkns (24.99% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): ve Technologies, Inc. (GITS) is up over 7% at $1.62. High-Trend International Group (HTCO) is up over 6% at $1.06.

In the Red

Humacyte, Inc. (HUMA) is down over 28% at $2.06. Tenon Medical, Inc. (TNON) is down over 23% at $2.88. Zhengye Biotechnology Holding Limited (ZYBT) is down over 16% at $6.85. Golden Heaven Group Holdings Ltd. (GDHG) is down over 16% at $3.19. Predictive Oncology Inc. (POAI) is down over 14% at $1.44. Galecto, Inc. (GLTO) is down over 12% at $4.30. FST Corp. (KBSX) is down over 11% at $2.53. Integrated Media Technology Limited (IMTE) is down over 10% at $1.70. Local Bounti Corporation (LOCL) is down over 8% at $1.84.

Copyright(c) 2025 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX© 2025 AFX News

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ZYBT_IN_8 [2025-04-16 12:38:48 -0400] 3 Bytes | 2 tokens | Cum: 2001 tkns (25.01% of 8k)
==========================================================================

NEX

ZYBT_OUT_9 [2025-04-16 12:38:50 -0400] 238 Bytes | 59 tokens | Cum: 2060 tkns (25.75% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ZYBT_IN_10 [2025-04-16 12:38:50 -0400] 3 Bytes | 2 tokens | Cum: 2062 tkns (25.77% of 8k)
==========================================================================

NEX

ZYBT_OUT_11 [2025-04-16 12:39:04 -0400] 4969 Bytes | 1174 tokens | Cum: 3236 tkns (40.45% of 8k)
==========================================================================

This is our set of metrics for Zhengye Biotechnology.
Please analyze the numbers.

+---------------------+----------------------+-----------------------+------------------------+
| Volume: 246,715 | Perf Month: 53.32% | Option/Short: No / No | Sales Y/Y TTM: -28.00% |
+---------------------+----------------------+-----------------------+------------------------+
| Avg Volume: 191.25K | Perf Quarter: 64.27% | Short Float: 1.60% | ROE: 7.51% |
+---------------------+----------------------+-----------------------+------------------------+
| Rel Volume: 2.74 | Index: - | Short Ratio: 0.37 | ROI: 7.24% |
+---------------------+----------------------+-----------------------+------------------------+
| RSI (14): 66.69 | Market Cap: 337.87M | Short Interest: 0.07M | Sales Surprise: - |
+---------------------+----------------------+-----------------------+------------------------+
| ATR (14): 1.07 | Shs Outstand: 47.17M | Beta: - | EPS Surprise: - |
+---------------------+----------------------+-----------------------+------------------------+
| SMA20: 38.75% | Shs Float: 4.43M | Sales Q/Q: -21.95% | P/E: 119.82 |
+---------------------+----------------------+-----------------------+------------------------+
| SMA50: 50.61% | Inst Own: - | Sales past 5Y: - | Earnings: - |
+---------------------+----------------------+-----------------------+------------------------+
| SMA200: 52.94% | Insider Own: 90.66% | Employees: - | |
+---------------------+----------------------+-----------------------+------------------------+
| Perf Week: 77.35% | Insider Trans: 0.00% | Debt/Eq: 0.31 | |
+---------------------+----------------------+-----------------------+------------------------+

The next section covers any insider trading by Zhengye Biotechnology officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.14
Average Volume: 456734.61
30-Day High: 8.2
30-Day Low: 3.64
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Zhengye Biotechnology (ZYBT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Zhengye Biotechnology.

2) MARKET_SCORE[]
This conversation was initiated because ZYBT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ZYBT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ZYBT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ZYBT to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Zhengye Biotechnology.

11) ETHICAL_RATING[]
Rate Zhengye Biotechnology’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Zhengye Biotechnology.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ZYBT_IN_12 [2025-04-16 12:39:04 -0400] 1004 Bytes | 220 tokens | Cum: 3456 tkns (43.20% of 8k)
==========================================================================

BRIEF_SUMMARY[Zhengye Biotechnology has experienced significant stock price and volume increases recently, with a remarkable performance over the last month and quarter. Despite these gains, the company has been struggling with declining sales year-over-year and quarter-over-quarter, which raises concerns about its fundamental health. High insider ownership and a low debt-to-equity ratio provide some stability, but the high P/E ratio suggests the stock might be overvalued given its current earnings.]

MARKET_SCORE[65]

PRICE_TARGET[7.71]

AI_RPT_HEADLINE[Zhengye Biotechnology Soars Amid Sales Decline, High Valuation]

SQUEEZE_POTENTIAL[30]

TAGS[biotech, high volatility, insider ownership, overvalued]

STOCK_TYPE[speculative]

PRIMARY_CATALYST[earnings report]

SENTIMENT[mixed]

IMPROVEMENT_SUGGESTION[More detailed recent quarterly financial data and forward-looking statements from management would enhance the analysis.]

ETHICAL_RATING[C]

UPCOMING_CATALYST[Next quarterly earnings report]

ZYBT_IN_13 [2025-04-16 12:39:04 -0400] 126 Bytes | 29 tokens | Cum: 3485 tkns (43.56% of 8k)
==========================================================================

====================================
[2025-04-16 12:39:04] # Analysis Completed
Elapsed Time: 19.73 seconds




Scroll to Top